Ashlie Arthur, DO
Pulmonary Disease · Fayetteville, GANPI 1558701847
Payments from drug & device makers
Across 161 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$810
- AstraZeneca$313
- Takeda Pharmaceuticals U.S.A., Inc.$304
- Boehringer Ingelheim$281
- Insmed, Inc.$136
- Grifols USA, LLC$121
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,035100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 55 | $810 |
| AstraZeneca(2 entities) | 17 | $313 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $304 |
| Boehringer Ingelheim | 16 | $281 |
| Insmed, Inc. | 5 | $136 |
| Grifols USA, LLC | 5 | $121 |
| Amgen | 7 | $116 |
| Axsome Therapeutics, Inc. | 3 | $108 |
| Mylan Specialty L.p. | 5 | $90 |
| Pfizer | 5 | $84 |
| Inspire Medical Systems, Inc. | 2 | $78 |
| Advanced Respiratory, Inc | 3 | $70 |
| Baxter Healthcare | 2 | $67 |
| Sanofi | 3 | $66 |
| Jazz Pharmaceuticals Inc. | 3 | $61 |
| Gilead | 3 | $54 |
| Verona Pharma, Inc. | 2 | $48 |
| Vifor Pharma, Inc. | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Merck | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| AbbVie | 1 | $19 |
| Resmed Corp | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$3,035 in reported general payments places this provider in the 35th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 388 | $273,459 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 121 | $77,132 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $35,331 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $33,722 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $29,728 |
| Spiriva RespimatTiotropium Bromide | 35 | $21,393 |
| EliquisApixaban | 35 | $19,627 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $13,193 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $12,703 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $10,132 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 293 | $7,309 |
| BreynaBudesonide/Formoterol Fumarate | 27 | $5,343 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $4,301 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,262 |
| Wixela InhubFluticasone Propion/Salmeterol | 38 | $2,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $810 | $352,645547 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $313 | $90,325168 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $281 | $51,12184 claims |
| PfizerEliquis | $84 | $19,62735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Fayetteville
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.